A B S T R A C T The activation and function of surfacebound Hageman factor in human plasma are dependent upon both high molecular weight (HMW) kininogen and prekallikrein. HMW kininogen does not affect the binding of Hageman factor to surfaces, but it enhances the function of surface-bound Hageman factor as assessed by its ability to activate prekallikrein and Factor XI. The initial conversion of prekallikrein to kallikrein by the surface-bound Hageman factor in the presence of HMW kininogen is followed by a rapid enzymatic activation of Hageman factor by kallikrein. The latter interaction is also facilitated by HMW kininogen. Kallikrein therefore functions as an activator of Hageman factor by a positive feedback mechanism and generates most of the activated Hageman factor during brief exposure of plasma to activating surfaces. HMW kininogen is a cofactor in the enzymatic activation of Hageman factor by kallikrein and it also augments the function of the activated Hageman factor generated. The stoichiometry of the Hageman factor interaction with HMW kininogen suggests that it enhances the activity of the active site of Hageman factor. Since HMW kininogen and prekallikrein circulate as a complex, HMW kininogen may also place the prekallikrein in an optimal position for its reciprocal interaction with Hageman factor to proceed. The surface appears to play a passive role upon which bound Hageman factor and the prekallikrein-HMW kininogen complex can interact.
INTRODUCTION
Hageman factor (1, 2), prekallikrein (3) (4) (5) , and high molecular weight kininogen (6) (7) (8) (9) (10) (11) have been shown to be critical constituents of the initiation phase of the intrinsic coagulation and fibrinolytic pathways as well as the generation of the vasoactive peptide, bradykinin. Two of these proteins, namely, prekallikrein and high molecular weight (HMW)l kininogen appear to circulate in plasma as a complex (12) . Upon binding to certain negatively charged surfaces, this complex presumably interacts with surface-bound Hageman factor. In this manuscript we have sought to further delineate the functions of the surface, prekallikrein, and HMW kininogen in the activation of Hageman factor and in the expression of Hageman factor activity.
An additional factor has been shown to be needed when surface-bound Hageman factor is used to activate either prekallikrein (13) or Factor XI (14) even though it is clear that activated Hageman factor is capable of activating prekallikrein (15) and Factor XI (16) in the fluid phase. Similarly, the feedback activation of Hageman factor by kallikrein that is demonstrable in the fluid phase (17, 18) does not appear to be evident in plasma that are deficient in HMW kininogen (6) (7) (8) (9) (10) (11) . Thus HMW kininogen might directly activate centrifuged at 900 g for 20 min at 4°C and the plasma was separated with plastic pipettes. Plastic columns and test tubes were utilized throughout all chromatographic procedures to minimize contact activation of Hageman factor. Samples were routinely concentrated by ultrafiltration through a UM-10 membrane (Amicon Corp., Lexington, Mass.). Gel filtration on Sephadex G-100 (15) or G-150 (19) alkaline disc gel electrophoresis (15) , and sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (20) were performed as previously described. Protein was estimated by absorbance at 280 nm, with A, 1% assumed to equal 10, or was determined by the Lowry technique (21) .
Radioiodination of proteins was performed by the chloramine-T method (22) using lu2I-sodium iodide. The iodinated protein was immediately fractionated on a 2 x 100-cm column of Sephadex G-50 in 0.003 M phosphate buffer 0.15 M NaCl, pH 8.0. The initial peak of radioactivity was completely separated from the peak of free iodine and, when concentrated, contained over 99% of the trichloroacetic acidprecipitable counts. Radioactivity was determined in a sodium iodide well scintillation counter (Searle Analytic Inc., Des Plaines, Ill., model 1185) with automatic subtraction of background and an efficiency of 82%.
[3H]DFP was counted in a Tri-Carb model 3375 liquid scintillation spectrometer (Packard Instrument Co., Inc., Downers Grove, Ill.) calibrated with a [3H]toluene standard with a counting efficiency of 45%.
Unactivated Hageman factor. Unactivated Hageman factor was isolated utilizing chromatography on QAE-Sephadex, elution from an anti-Hageman factor immunoadsorbent, and fractionation on SP-Sephadex as previously reported (23, 24) . 2 liters of fresh human plasma collected as described above was made 1 mM in DFP, dialyzed at 40C for 12 h against four 30-liter changes of 0.003 M P04 buffer pH 8.3, and again made 1 mM in DFP. The plasma was centrifuged at 900g for 15 min to remove any precipitate that had formed and was applied to a 18.5 x 90-cm column of QAE-Sephadex equilibrated in the same buffer. All subsequent buffers were made 0.1 mM in DFP to inhibit enzymatic activation of the Hageman factor. The column was washed with 30 liters of equilibrating buffer and the effluent was used subsequently to obtain prekallikrein and Factor XI. Unactivated Hageman factor was then eluted from the column with 30 liters of 0.003 M P04 buffer containing 0.06 M NaCl pH 8.3. The unactivated Hageman factor peak was concentrated to 1 liter by ultrafiltration using a 150-mm UM-10 membrane and the concentrate was then passed over a 9 x 20-cm immunoadsorbent prepared with sheep anti-human Hageman factor coupled to Sepharose 4B. The column was washed with 10 liters of 0.003 M P04 buffer 0.35 M NaCl, pH 7.4 , and the Hageman factor was eluted with 500 ml 1 M potassium thiocyanate in 0.003 M P04 buffer pH 8 .0. The unactivated Hageman factor peak was pooled, concentrated to 200 ml, dialyzed overnight against 10 liters of 0.003 M P04 buffer pH 6.0 and fractionated on a 9 x 76-cm column of SPSephadex equilibrated with the same buffer. The column was washed with 4 liters equilibrating buffer and then with 2 liters equilibrating buffer containing 0.09 M NaCl. A linear gradient consisting of 4 liters 0.003 M P04 buffer with 0.09 M NaCl pH 6.0 and 4 liters 0.003 M P04 with 0.35 M NaCl pH 6.0 was then applied. The unactivated Hageman factor peak eluting between 0.15 and 0.20 M NaCl was pooled and concentrated to 35 ml. When the Hageman factor preparation was assessed by alkaline disc gel electrophoresis, one major and two minor bands were observed. Elution of a sliced, unstained, alkaline disc gel run simultaneously revealed that these bands coincided with the Hageman factor activity. When the preparation was subjected to SDS gel electrophoresis, a single band at mol wt 82,000 was observed. The final preparation at a concentration of 20 Aig/ml corrected the activated partial thromboplastin time (PTT) of Hageman factor-deficient plasma from a control time of 31 min-1 min, 20 s. This represents 0.6 U/ml when Activation and Function of Human Hageman Factorthe Hageman factor activity of a pool of 10 normal plasmas was arbitrarily set at 1.0 U/ml. Samples were dialyzed against phosphate-buffered saline before assay to remove the DFP. The Hageman factor contained less than 1% activated Hageman factor and was free of detectable kininogen, Factor XI, prekallikrein, plasminogen, or ability to cleave BPVAN.
The anti-Hageman factor immunoadsorbent (24) was prepared as follows: Hageman factor isolated from 200 ml of plasma by chromatography on QAE-Sephadex and SPSephadex was concentrated and emulsified in complete Freund's adjuvant. A sheep was immunized intramuscularly and then boosted intradermally three times at 2-wk intervals using the Hageman factor preparation emulsified in incomplete Freund's adjuvant. The animal was bled and the serum absorbed with 20% (by volume) Hageman factordeficient plasma. 500 ml of absorbed sheep serum was then made 45% in ammonium sulfate, the precipitate was dissolved in 200 ml distilled water, dialyzed against 0.003 M P04 buffer 0.15 M NaCl pH 8.0, and coupled to Sepharose 4B by the cyanogen bromide method (25) . Activated Hagemanfactor. Activated Hageman factor was prepared in a similar fashion as the precursor; however, DFP was eliminated from the buffers and CM-cellulose was substituted for SP-Sephadex. The 0.06 M NaCl eluate from QAESephadex was concentrated, stirred in a glass vessel overnight, and fractionated on CM-cellulose. The Hageman factor was then concentrated to 10 ml and fractionated on a 5 x 100-cm column of Sephadex G-100 to remove Hageman factor fragments. The preparation was active upon the Hageman factor substrates and, when utilized at a concentration of 20 /.g/ml, corrected the coagulation defect of Hageman factor-deficient plasma from a control time of 30 min-1 min, 35 s in the presence or absence of kaolin, indicating that the preparation was completely activated. It had no effect upon Factor XI-deficient plasma. Its mol wt was 80,000 in unreduced SDS gels.
Hageman factor fragments. Hageman factor prealbumin fragments were purified by chromatography of plasma on QAE-Sephadex twice, Sephadex G-100 gel filtration, SPSephadex, and elution from alkaline disc gels after electrophoresis, as previously reported (15, 23) . 20-ug Hageman factor fragments revealed two prealbumin bands upon disc gel electrophoresis and a single band at mol wt 28,000 upon SDS gel electrophoresis. After dialysis, the fragments were concentrated and routinely used at 25,g/ml. When assessed functionally, 5 ,ul of Hageman factor fragment generated 100 ng of bradykinin after incubation with 0.2 ml fresh plasma for 2 min at 37°C as assessed by bioassay. There was no detectable contamination with any of the Hageman factor substrates, plasminogen, plasmin, or kininogen.
Hageman factor substrates. Factor XI and prekallikrein were isolated from the QAE-Sephadex effluent obtained above during the isolation of unactivated Hageman factor. The proenzyme mixture was concentrated to 500 ml by ultrafiltration, the pH brought to pH 6.0 with 1 N HCI and each substrate was isolated by sequential chromatography on SP-Sephadex, twice on Sephadex G-150 (26) , and passage over an anti-IgG immunoadsorbent as described previously (26, 27) . All buffers were made 1 mM in DFP. When 30 ug of prekallikrein (2 mg/ml) was subjected to alkaline disc gel electrophoresis or SDS gel electrophoresis, a single band was observed and it contained no detectable Factor XI. 15 ,l of this preparation (10 i.g/ml) incubated with 15-,ul Hageman factor fragments (2.5 ,Lg/ml) generated 150 ng bradykinin from 0.2 ml of heat-inactivated plasma (15) . The Factor XI preparation had a single band upon disc gel or SDS gel electrophoresis (mol wt 160,000), contained no detectable prekallikrein or kallikrein, and completely corrected Factor XI-deficient plasma at a concentration of 7 The antikininogen immunoadsorbent was prepared as follows: sheep anti-low molecular weight (LMW) kininogen (30) was passed over a column of LMW kininogen coupled to agarose by the cyanogen bromide procedure (25) . The antikininogen was eluted with 8 M guanidine, the eluate was dialyzed against phosphate-buffered saline, and the purified antikininogen was coupled to agarose by the cyanogen bromide procedure (25) . In this fashion a high-capacity column that specifically binds kininogen was prepared. Since antibody to LMW kininogen cross-reacts with HMW kininogen (29) 
Assays
Coagulation assays. The PTT was measured by a modification of the method of Proctor and Rapaport (32); after recalcification, the end point was determined at 24°C. Factor XI, Hageman factor, prekallikrein, and HMW kininogen were determined by a modification of the PTT using congenitally deficient plasma (9) . Activated Hageman factor and Factor XIA were assayed in an identical fashion except that kaolin was omitted from the incubation mixture. All coagulation assays were performed in 10 x 75-mm polypropylene test tubes.
Fibrinolytic assays. Plasmin was assayed with Hyland fibrin plates (Hyland Div., Travenol Laboratories, Inc.) containing plasminogen-free human fibrin as previously described (26) . A standard curve relating ring diameter to plasmin concentration was obtained by activating 0.2 ml of a reference preparation of purified plasminogen containing 250
,ug/ml with 140 U of streptokinase for 30 min at 37°C; a linear plot relating log plasmin concentration to ring diameter was obtained between 3 and 250 Ag plasminogen/ml.
Plasminogen was assayed by incubating 0.2 ml of plasminogen source with 140 U streptokinase for 30 min at 37°C and determining the plasmin generated by the fibrin plate assay.
Plasminogen activator activity was assayed by incubating 20
,ul of a plasminogen activator source with 20 ,ul of plasminogen (200,Lg/ml) for 1 h at 370C, and determining the plasmin generated in a fibrin plate. Plasminogen proactivator activity was assayed by incubation of 10 ,ul plasminogen proactivator source with 10-,l Hageman factor fragments (25 ,ug/ml) for 10 min at 37°C. 20
,ul of plasminogen (200 ,ug/ml) was added, the mixture was incubated for 1 h at 37°C, and the plasmin generated was determined by the fibrin plate assay.
The rate of generation of kaolin-activated fibrinolytic activity of plasma was assessed by a modification of the procedure described by Ogston et al. (33) . To 0.2 ml of plasma or 0.1 ml of plasma and 0.1 ml test sample were added 0.1 ml kaolin suspension (4 mg/ml in saline) and 3.7 ml 0.01 M sodium acetate buffer, pH 4.8. After incubation at 37°C, the samples were centrifuged at 900 g for 10 min at 40C, the supernate was aspirated, and the precipitate was washed with 2.0 ml 0.01 M sodium acetate buffer pH 4.8 and again centrifuged at 900g for 10 min at 4°C. The precipitate obtained was dissolved in 0.1 ml 0.003 M P04 buffer, pH 7.5, containing 0.15 M NaCl, and centrifuged at 900 g for 5 min to sediment the kaolin. The supernate was then assayed for plasmin by the fibrin plate assay.
Assays of kinin-forming enzymes and substrates. Kallikrein activity was assayed by its ability to cleave pnitroaniline from the synthetic substrate BPVAN (34). 10-100 ,ul of kallikrein source was incubated with 100 IAl of substrate (0.7 mg/ml) for 60 min at room temperature, the sample was diluted to 1.0 ml, and the release of p-nitroaniline was determined by its absorbance at 405 nm. Initial experiments showed that the liberation of p-nitroaniline was proportional to the kallikrein concentration between 0.05 and 30.0 ug kallikrein/ml and was linear for a given concentration of kallikrein up to 60 min. The proteolytic activity of kallikrein was measured by its ability to release bradykinin from heat-inactivated plasma (15) . Routinely, 25 JAI of kallikrein source was incubated with 0.2 ml substrate for 2 min at 37°C and the bradykinin liberated was quantitated by bioassay.
Prekallikrein was determined by incubation of 25 ,ul of proenzyme source with 25 ,lA of Hageman factor fragments (25 ,ug/ml) for 5 min at 370C and the kallikrein generated was determined. Kininogen was assayed functionally from column fractions by incubation of 0.5 ml of each fraction with 1 Mug trypsin for 30 min at 37°C. The trypsin was inactivated by heating for 15 min in a boiling water bath, and the bradykinin generated was determined by bioassay. The ability of highly purified B4y kininogen (1 mg/ml) to generate bradykinin upon incubation with plasma kallikrein was determined by incubating 100 ug kininogen with 100 gl of kallikrein (50 ,ug/ml) for 10 min at 37°C.
Determination of the effect of HMW kininogen and/or kallikrein upon surface-bound Hageman factor. Assessment of the requirements for surface activation of Hageman factor was performed by a modification of the method of Webster and Pierce (13) . 5 mg of supercel was washed once with 0.04 M Tris-HCl-0.15 M NaCl pH 8.0, centrifuged at 1,000 g for 5 min at 4°C and the supernate was discarded. Buffer was then added to the pellet followed by the reactants (Hageman factor, HMW kininogen, kallikrein) such that the final volume was 1.0 ml. The suspension was then mixed by vortexing for 10 s, and incubated at either 40, 240, or 37°C for varying time intervals. The mixture was centrifuged at 1,000 g for 5 min at 4°C and the pellet washed three times with the Tris-saline buffer. This activation mixture was then assayed for activated Hageman factor by incubation with the Hageman factor substrates thus separating the reaction into two steps. The pellet was resuspended in 0.5 ml of a 10-ug/ml solution containing prekallikrein or Factor XI, and incubated at 24°C for 5 min to 1 h. The suspension was then centrifuged at 1,000 g for 5 min at 4°C, the supernate was removed and an aliquot assayed for either kallikrein, Factor XIA, or plasminogen activating activity, respectively. In these experiments Factor XIA was assayed by mixing 50 Mul of each of the reactants (sample, cephalin reagent, calcium, and Factor XI-deficient plasma) and determining the time for formation of a clot at 370C in the absence of any preincubation. Kallikrein and plasminogen activator were assayed as described above. In this two-stage reaction the conditions utilized allowed little binding of the Hageman factor substrates to the supercel pellet during the final incubation. In separate experiments we determined that the quantity of prekallikrein and Factor XI bound to the supercel under these conditions was less than 10% of that added. Of the fraction of prekallikrein and Factor XI activated to kallikrein and Factor XIA, <2% of the kallikrein was bound to the surface, while 5-10% of the Factor XIA was bound.
The quantity of Hageman factor bound to the supercel surface was determined by adding a trace quantity of 125I-Hageman factor (1.2 MCi/,ug) to purified unactivated Hageman factor. The fraction of bound 125I was determined and multiplied by the initial Hageman factor added to determine the quantity bound.
RESULTS
To determine the conditions for optimal activation of Hageman factor, a time-course of interaction of Hageman factor and HMW kininogen with supercel was determined. 1 ,ug of Hageman factor, 3 Mig of HMW kininogen or a mixture of 1 Mug of Hageman factor and 3 ,ug of HMW kininogen were incubated with the supercel for varying time intervals before centrifugation. An Fig. 3 , the bound Hageman factor alone was capable of activating each substrate. When 6 ,ug of HMW kininogen alone was incubated with supercel and the washed pellet then incubated with the Hageman factor substrates, no significant activation was observed although a small quantity of free bradykinin was detectable in the kininogen preparation. When HMW kininogen was added to the supercel together with the Hageman factor, the ability of Hageman factor to activate each substrate was augmented and the increase in observed activity in each case appeared proportional to the concentration of HMW kininogen added. When equal concentrations of B2a LMW kininogen was similarly assessed, there was no augmentation ofthe ability of surface-bound Hageman factor to activate its substrates. HMW kininogen had no effect upon the ability of kallikrein to cleave BPVAN nor did it affect the coagulant activity of activated Factor XI.
To determine the optimal quantity of HMW kininogen required to augment the activity of a fixed quantity of Hageman factor, 1.5 ,ug Hageman factor was bound to supercel and its ability to convert prekallikrein to kallikrein was determined after addition of either buffer or increasing concentrations of HMW kininogen. The enhancement obtained with each dose of HMW kininogen was then expressed as a function of the micrograms of HMW kininogen added. As shown in Fig. 4 Fig. 6 illustrates the comparison of the rate of generation of kaolin-activable coagulation and fibrinolysis in normal plasma compared to plasma deficient in Hageman factor, prekallikrein, and HMW kininogen. The Hageman factor-deficient plasma had a markedly prolonged PTT (Fig. 6A ) and generated no detectable plasmin (Fig. 6B) . The HMW kininogen-deficient plasma had a similarly prolonged PTT (Fig. 6A) and generated a minimal quantity of plasmin (Fig. 6B) . The prekallikrein-deficient plasma had an abnormal PTT and generated little plasmin at 2 min; however when the time of incubation with kaolin was increased, the PTT diminished and approached normal (Fig. 6A ) and plasmin generation gradually increased (Fig. 6B) . In contrast the normal plasma had a short PTT and rapidly generated plasmin within 3 min of incubation with kaolin. Since the prekallikrein-deficient plasma initially generated little plasmin and had a prolonged PTT, the major activation of Hageman factor occurring within the first few minutes appeared to be a function ofthe prekallikrein content. Yet plasma that is deficient in HMW kininogen but contains prekallikrein did not express this effect of prekallikrein upon Hageman factor activation.
We next assessed the surface and enzymatic conditions required to correct the coagulation abnormality of prekallikrein-deficient plasma. As shown in Table I , the PTT of the prekallikrein-deficient plasma was 32 min in the absence of kaolin and 6 min, 15 s in the presence of kaolin. The PTT could be corrected to 1 min, 30 s by addition of 10 ,ug/ml of intact activated Hageman factor in the absence of kaolin indicating that the abnormality lies in the rate of formation of activated Hageman factor. Addition of 3 ,ug of kallikrein in the absence of kaolin did not yield a significant shortening of the PTT, while the addition of the same amount of kallikrein in the presence of kaolin corrected the PTT to 1 min, 20 s. 3 gg of DFP-treated kallikrein (which was inactive as a kinin-forming enzyme) did not shorten the PTT even in the presence of kaolin indicating that the active site of kallikrein is necessary. In the presence of kaolin, 3 ug of DFP-treated prekallikrein corrected the PTT as well as 3 ,Lg of untreated prekallikrein. Since the active-site serine residue in prekallikrein is unavailable to DFP (19) subsequent conversion to kallikrein would then yield a functional enzyme. Thus, correction of prekallikrein deficiency appeared to require conversion of prekallikrein to kallikrein, thus generating an active site and the kallikrein interacted with Hageman factor only in the presence of a surface. DFP treatment of HMW kininogen had no effect upon its ability to correct the coagulation abnormality in HWM kininogendeficient plasma.
The ability of kallikrein to activate Hageman factor was next studied using purified components bound to the supercel surface. 1 ,ug of unactivated Hageman factor was incubated with supercel in the presence of either buffer, 0.5 ,ug ofkallikrein, 3 Ag of HMW kininogen, or a mixture of 0.5 ,ug of kallikrein and 3 ug of HMW kininogen. After incubation the suspensions were centrifuged, the pellets were washed three times with Tris-saline buffer, and the resuspended pellets were assayed for their ability to activate prekallikrein. Activation of prekallikrein was observed with the bound Hageman factor alone, and addition of 0.5 jig of kallikrein to the Hageman factor yielded a small increment in the subsequent conversion of prekallikrein to kallikrein (Fig. 7) . The As evident in Fig. 6 , most of the activated Hageman factor generated in normal plasma occurred within the first 2 or 3 min of incubation with the surface. This activation was dependent upon the presence of prekallikrein. Therefore the ability of kallikrein to activate Hageman factor in the presence or absence of HMW kininogen was evaluated under conditions such that the resuspended pellet containing HMW kininogen and Hageman factor possessed minimal ability to convert prekallikrein to kallikrein. All reagents (except kallikrein) were made 10 mM in DFP and incubated for 90 min at 37°C to inhibit any trace of activated enzyme. Each protein was dialyzed extensively to remove the excess DFP. 1 ug Hageman factor in the presence or absence of 4.5 ug HMW kininogen was incubated with varying quantities of kallikrein. The washed pellet was then assayed for its ability to convert prekallikrein to kallikrein, however the incubation time with prekallikrein was decreased to 10 min at 24°C. As shown in Fig. 9 , the addition of kallikrein to the bound Hageman factor in the absence of HMW kininogen did not yield a significant conversion of prekallikrein to kallikrein. The Hageman factor-HMW kininogen mixture (with no kallikrein) yielded little activity above that of the Hageman factor alone. However addition of increasing quantities of kallikrein to the Hageman factor-HMW kininogen mixture yielded a rapid increase in amidolysis indicating an augmentation of the activated Hageman factor detected. In contrast to the 3-fold enhancement observed with HMW kininogen-alone in previous experiments, the enhancement observed upon addition of kallikrein to the Hageman factor-HMW kininogen mixture was approximately 40-fold. Since kallikrein appeared to activate Hageman factor in the presence of HMW kininogen, we next compared the incorporation of [3H]DFP into surfacebound Hageman factor upon addition of HMW kininogen, kallikrein, and a mixture of HMW kininogen and kallikrein. Triplicate samples containing 1.0 ,ug Hageman factor were incubated with supercel in the pres- min inctubation. The pellets were then centrifuged at 1,000 g for 10 min at 40C and the pellets were washed with 12% trichloroacetic acid until the supernate was free of counts. The pellets were then suspended in 10 ml Aquasol and counted. As shown in Table II and kinin-generation attributable to HMW kininogen deficiency (6, 7) , and, Colman et al. reported a patient who had no detectable kininogen and whose functional abnormalities were attributed to a new factor (8) which was independently identified to be HMW kininogen (9) . Confirmation of these observations appeared shortly thereafter when Fitzgerald trait, an abnormal plasma described earlier by Saito et al. (10) was also shown to be deficient in HMW kininogen (11) .
In an attempt to more precisely localize the role of HMW kininogen in coagulation, Saito et al. observed that activated Factor XI functions normally in HMW kininogen-deficient plasma (10) indicating that the contribution of HMW kininogen must precede the formation of Factor XI. We have shown that HMW kininogen enhanced the action of surface-bound Hageman factor upon each of its substrates (Fig. 3) , as reported in preliminary form (35) , but did not increase the incorporation of [3H]DFP into surface-bound Hageman factor (Table II) . Thus HMW kininogen did not activate surface-bound Hageman factor but appeared to augment the function of the activated molecule. Liu et al. (36) reported a similar functional enhancement when the activity of Hageman factor fragments was assessed in the presence and absence of HMW kininogen (Fig. 5) . In this case, a surface is not necessary since the fragments are already active, and the enhancement observed with HMW kininogen is clearly an effect upon the function of Hageman factor. The interaction of activated Hageman factor and HMW kininogen appears to be stoichiometric since the percentage enhancement of Hageman factor activity is directly proportional to the quantity of HMW kininogen added and further addition of HMW kininogen yields a gradual inhibition of Hageman factor activation. Schiffman and Lee have reported such an incremental increase in the quantity of Factor XIA formed when increasing amounts of "contact activation cofactor" were added to surface-bound Hageman factor preparations (37). Griffin and Cochrane (38, 39) Hageman factor is then added to this plasma, its function can be augmented by the HMW kininogen present. The gradual activation of Hageman factor observed upon incubation of prekallikrein-deficient plasma with kaolin ( Fig. 6) (3-5) may reflect the gradual formation of the active site of Hageman factor upon the surface as well as augmentation of the function of that site by HMW kininogen. Enzymatic activation of the Hageman factor by enzymes such as plasmin (40) or Factor XIA (17) may function instead of kallikrein and contribute to this autocorrection with time. It has been shown that kallikrein can activate and fragment Hageman factor in the fluid phase; yet addition of kallikrein to prekallikreindeficient plasma in the absence of a surface does not generate activated Hageman factor (Table I) (5, 27) . Thus the critical activation of Hageman factor by kallikrein takes place upon a surface. Since the active site of kallikrein is required for this interaction (Table I) 
